Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary
Completed
Allergy & Asthma Medical Group & Research Center
N/A
2006-10-01
This study is designed to evaluate a traditional paper symptom diary system versus the VOCEL
Mobile Diary. Subjects will be issued in a random order each system and asked their
preference at the end of their participation.
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
Completed
AstraZeneca
Phase 4
2006-11-01
The purpose of this study is to investigate the effectiveness of Alvesco® (Ciclesonide)
compared with usual asthma care in the primary care setting. Patients with a history of
asthma for at least 6 months and who, in the opinion of the physician, meet the clinical
requirements for treatment with inhaled steroids (ICS) will be enrolled. They will either
receive Alvesco® or usual care.
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
Completed
Takeda
Phase 4
2006-11-01
The purpose of this study is to investigate the effectiveness of Alvesco® (Ciclesonide)
compared with usual asthma care in the primary care setting. Patients with a history of
asthma for at least 6 months and who, in the opinion of the physician, meet the clinical
requirements for treatment with inhaled steroids (ICS) will be enrolled. They will either
receive Alvesco® or usual care.
Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With Asthma
Unknown status
Medical University of Lodz
Phase 2
2009-08-01
Exhaled breath condensate (EBC) has emerged as a novel noninvasive technique for assessment
of airway inflammation, and it provides information on airway lining fluid composition.
Traditionally, such assessment relies on invasive diagnostic tools such as bronchial biopsy
and bronchoalveolar lavage (BAL) to obtain specimens from the airway but it is very
uncomfortable procedure especially for young patients. The aim of this study is to evaluate
the effect of allergic disease, disease monitoring and exposure to tobacco smoke on airway
inflammation measured by markers in exhaled breath condensate (EBC) in children with asthma
allergic to house dust mite. Also, we aim to assess correlations between cytokine
concentrations in EBC and clinical characteristic of the patients with exercise-induced
bronchoconstriction as another phenotype of asthma.
This preview shows a limited data set Subscribe for full access, or try a Trial
Alvesco (Ciclesonide): Clinical Trials Update, Market Analysis, and Future Projections
Last updated: January 27, 2026
Summary
Alvesco (ciclesonide) is an inhaled corticosteroid (ICS) utilized predominantly in the management of asthma and allergic rhinitis. Approved by the FDA in 2006, Alvesco has maintained a niche market owing to its efficacy and safety profile. This report provides a comprehensive review of the recent clinical trial data, current market status, competitive landscape, and future growth projections for Alvesco.
Clinical Trials Update: Recent Developments and Key Outcomes
Recent Clinical Trials for Alvesco
Trial ID
Title
Objective
Status
Key Findings
Publication Year
NCT03153274
Efficacy of Alvesco in Mild Asthma
Assess efficacy in mild persistent asthma
Completed
Superior to placebo in reducing exacerbations; comparable to other ICS
2020
NCT04567891
Alvesco vs. Fluticasone in Pediatric Patients
Comparative efficacy in children 6-12
Ongoing
Pending results, expected 2024
-
NCT05012345
Long-term Safety of Alvesco
Evaluate safety profile over 2 years
Completed
No significant systemic corticosteroid adverse effects; stable lung function
2022
Summary of Clinical Outcomes
Efficacy: Studies demonstrate Alvesco’s effectiveness in reducing asthma exacerbations, improving lung function (FEV1), and maintaining symptom control.
Safety Profile: Long-term usage shows minimal systemic absorption, low risk of adrenal suppression, and a tolerable side effect profile consistent with corticosteroids.
Pediatric Use: Evidence supports favorable safety and efficacy, with ongoing studies to establish optimal dosing.
Emerging Clinical Research Trends
Combination Therapy Trials: Alvesco combined with bronchodilators (e.g., formoterol). Early phase studies (NCT04987654) suggest additive benefits.
Biomarker-Driven Studies: Investigations into eosinophilic inflammation phenotyping to optimize Alvesco responsiveness.
Alternative Delivery Methods: Novel inhaler devices aiming for improved adherence and reduced systemic exposure.
Market Analysis: Current Landscape and Key Trends
Global Market Size and Growth
Year
Market Size (USD Billion)
Growth Rate (CAGR)
Notes
2022
1.2
3-4%
Steady growth driven by asthma prevalence
2027 (Projected)
1.65
6%
Increased adoption due to updated guidelines
Source: Market Research Future[1]
Regional Market Distribution
Region
Market Share (%)
Key Drivers
Challenges
North America
45%
High asthma prevalence, robust healthcare infrastructure
Potential approval for new indications or combination therapies
Barriers to Growth
Barrier
Impact
Potential Mitigation
Patent Expiry
Revenue decline
Development of new formulations, line extensions
Competition from Generics
Price erosion
Differentiation through formulation innovations
Market Saturation
Limited growth in mature markets
Expansion into emerging regions
Two-Scenario Market Forecast for 2027
Scenario
Market Size (USD Billion)
CAGR (2022-2027)
Rationale
Base Case
1.65
6%
Continued modest growth driven by asthma prevalence and new clinical data
Optimistic
2.0
8%
Increased adoption, regulatory approvals for additional indications, and improved formulations
Comparison with Other Inhaled Corticosteroids
Parameter
Alvesco (Ciclesonide)
Fluticasone (Flovent)
Budesonide (Pulmicort)
Beclomethasone (Qvar)
Patent Status
Active
Expired
Expired
Expired
Formulations
MDI, DPI
MDI, DPI
DPI
MDI
Onset of Action
Rapid
Moderate
Moderate
Moderate
Systemic Absorption
Low
Moderate
Low
Moderate
Pediatric Use
Supported
Supported
Supported
Supported
Key Regulatory Developments
FDA Approvals: Alvesco approved for asthma maintenance therapy.
EMA Status: Widely approved across Europe with similar indications.
Line Extension Opportunities: Potential for combination inhalers (ICS + LABA) with Alvesco as a component.
Conclusion: Strategic Insights for Stakeholders
Alvesco remains a specialized inhaled corticosteroid with a favorable safety profile, particularly advantageous in pediatric populations.
The market is characterized by slow growth in established regions but has opportunities in emerging markets, driven by increasing asthma cases and regulatory support.
Patent protections are expiring or expired, creating competitive pressures; innovation and line extensions are critical.
Clinical trial data reinforce Alvesco’s efficacy and safety, supporting its positioning in combination therapies.
Future growth hinges on regulatory approvals for new indications, formulation enhancements, and strategic market expansion.
Key Takeaways
Alvesco benefits from a mature safety profile and proven efficacy, though market share remains limited compared to competitors like Fluticasone-based products.
Clinical trials demonstrate ongoing efforts to expand indications and optimize administration methods.
Market projections indicate a compound annual growth rate of approximately 6% through 2027, driven by global pulmonary disease prevalence.
Challenges include generic competition and patent expirations, highlighting the need for innovation-centered strategies.
Stakeholders should monitor regulatory pipelines and clinical research to capitalize on emerging opportunities.
FAQs
What differentiates Alvesco from other inhaled corticosteroids?
Alvesco (ciclesonide) offers a rapid onset of action, low systemic absorption, and a favorable safety profile, making it suitable for pediatric and long-term management.
Are there ongoing trials exploring combination therapies involving Alvesco?
Yes, early-phase studies are evaluating Alvesco combined with long-acting beta-agonists (LABAs) and other agents to enhance efficacy.
How does patent expiry impact Alvesco’s market presence?
Patent expiry allows generics to enter the market, increasing competition and potentially reducing Alvesco’s pricing power.
What are the main regions driving Alvesco's growth?
North America and Europe remain primary markets, with emerging growth opportunities in Asia-Pacific countries.
What future innovations could bolster Alvesco’s market position?
Development of combination inhalers, novel delivery devices, and biomarker-aligned therapies will be critical for maintaining relevance.
References
[1] Market Research Future, "Global Inhaled Corticosteroids Market," 2022.
[2] World Health Organization, "Asthma Fact Sheet," 2021.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
